Annexin A1 Expression in Renal Cell Carcinoma
Posted: Monday, December 17, 2018
In gastric and hepatocellular carcinomas, the protein annexin A1 is overexpressed, and its upregulation is associated with malignancy. A Japanese study, published in the International Journal of Urology, revealed similar findings in patients with renal cell carcinoma. The researchers found that in this population, high annexin A1 expression in the tumor cell membrane appears to be associated with shorter disease-free survival and worse prognosis compared with weak or no annexin A1 expression.
“In the renal cell carcinoma cell line, annexin A1 knockdown cells showed significantly decreased proliferation, invasion, motility, and adhesion relative to control cells,” explained Mariko Yamanoi, MD, PhD, of the Shinshu University School of Medicine, Matsumoto, Japan, and colleagues, “showing a potential pathway regulated by annexin A1.”
The expression of annexin A1 was evaluated in renal cell carcinoma specimens from 27 patients. In approximately one-half (n = 13), annexin A1 was highly expressed in the membrane of renal cell carcinoma tumor cells. The remaining patients (n = 14) had weak or negligible annexin A1 expression in cell membranes. All patients with weak protein expression were free of renal cell carcinoma recurrence during the 8-year follow-up period, whereas those with high expression had significantly worse disease-free survival (P = .031). An analysis of patients with clear cell renal cell carcinoma revealed similar results.
“Exploitation of annexin A1 as a drug target might improve the prognosis for [renal cell carcinoma] patients,” concluded Dr. Yamanoi and colleagues.